Study to Explore Drug-drug Interactions Between DWC20155 and DWC20156 in Healthy Subjects

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: DWC20156; Drug: DWC20155

• Registration Number: NCT02704559
• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.

Brief Summary

A randomized, open-label, oral dose, crossover study to explore drug-drug interactions between DWC20155 and DWC20156 in healthy subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-12
• Primary Completion: 2016-02
• Study Completion: 2016-02
• Study First Submitted: 2016-02-27
• Study First Submitted QC: 2016-03-05
• Study First Posted: 2016-03-10
• Status Verified: 2017-02
• Last Update Submitted: 2017-02-14
• Last Update Posted: 2017-02-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Accepts healthy volunteers.

Exclusion Criteria

• Who has allergy to investigational product

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Study effect of DWC20156 on DWC20155 PK	DWC20156	To study effect of DWC20156 on DWC20155 PK
Study effect of DWC20155 on DWC20156 PK	DWC20155	To study effect of DWC20155 on DWC20156 PK

Primary Outcome Measures

Name	Time	Method
Peak Plasma Concentration (Cmax)	0~24hr
Area under the plasma concentration versus time curve (AUC)	0~24h

Trial Locations

Locations (1)

Busan Paik Hospital; 🇰🇷 Busan, Korea, Republic of